FacebookX(旧Twitter)Instagram

業績一覧（論文業績）

論文業績学会発表賞罰・研究助成

論文業績

英文原著

  1. Olivera P, Zuily S, Kotze P, Regnault V,Al Awadhi S,Bossuyt P, Gearry R, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng S, Papa A, Raine T, Teixeira F, Rubin D, Danese S, and Laurent Peyrin-Biroulet. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology. 18(12):857-873. 2021
  2. Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Intestinal Research 19(1):53-61. 2021
  3. Watanabe C, Nagahori M, Fujii T, Yokoyama K, Yoshimura N, Kobayashi T, Yamagami H, Kitamura K, Takashi K, Nakamura S, Naganuma M, Ishihara S, Esaki M, Yonezawa M, Kunisaki R, Sakuraba A, Kuji N, Miura S, Hibi T, Suzuki Y, Hokari R. Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Dig Dis Sci. 66(2):577-586. 2021
  4. Higashiyama M ,Komoto S, Suzuki Y, Watanabe M, Hibi T, Miura S, Hokari R. Relation of Geriatric Nutritional Risk Index With Clinical Risks in Elderly-Onset Ulcerative Colitis. J Gastroenterol Hepatol 36(1):163-170. 2021
  5. Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M. Intestinal cancer in patients with Crohn's disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 36(2):329-336. 2021
  6. Crooks B, McLaughlin J, Matsuoka K ,Kobayashi T , Yamazaki H , Limdi JK. The dietary practices and beliefs of people living with inactive ulcerative colitis. Eur J Gastroenterol Hepatol 33(3):372-379. 2021
  7. Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M. Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. J Gastroenterol Hepatol 36(4):864-872. 2021
  8. Vermeire S, Su C, Lawendy N, Kobayashi T , Sandborn W J, Rubin D T, Modesto I, Gardiner S , Kulisek N, Zhang H, Wang W, Panés J. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomized RIVETING Trial J Crohns Colitis 15(7):1130-1141. 2021
  9. Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 36(7):1744-1753. 2021
  10. Suzuki K , Kakuta Y , Naito T , Takagawa T , Hanai H, Araki H , Sasaki Y , Sakuraba H, Sasaki M , Hisamatsu H, Motoya S, Matsumoto T ,Onodera M , Ishiguro Y , Nakase H , Andoh A, Hiraoka S ,Shinozaki M , Fujii T , Katsurada T , Kobayashi T, Fujiya M, Otsuka T , Oshima N , Suzuki Y , Sato Y , Hokari R , Noguchi M , Ohta Y , Matsuura M, Kawai Y , Tokunaga K , Nagasaki M , Kudo H , Minegishi N , Okamoto D , Shimoyama Y , Moroi R , Kuroha M , Shiga H , Dalin Li , Dermot P B McGovern , Kinouchi Y , Masamune A , MENDEL study group. Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. Jan 27;izab004. doi: 10.1093/ibd/izab004. Online ahead of print. 2021
  11. Kita T, Ashizuka S, Ohmiya N, Yamamoto T, Kanai T, Motoya S, Hirai F, Nakase H, Moriyama T, Nakamura M, Suzuki Y, Kanmura S, Kobayashi T, Ohi H, Nozaki R, Mitsuyama K. Yamamoto S, Inatsu H, Watanbe K, Hibi T, Kitamura K. Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. J Gastroenterol. 56(2):147–157. 2021
  12. Matsubayashi M, Kobayashi T, Okabayashi S, Nakano M, Sagami S, Ozaki R, Kiyohara H, Morikubo H, Asonuma K, Miyatani Y, Maeda S, Hibi T. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. J Gastroenterol Hepatol. 36(4):943-950. 2021
  13. Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Kinoshita K, Alocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients with Inflammatory Bowel Diseases: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 19(5):908-921. 2021
  14. Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Fumihito H, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol 56(6):560-569. 2021
  15. Shen B, Kochhar GS, Navaneethan U, Cross RK, Farraye FA, Iacucci M, Schwartz DA, Gonzalez-Lama Y, Schairer J, Kiran RP, Kotze PG, Kobayashi T, Bortlik M, Liu X, Levy AN, González Suárez B, Tang SJ, Coelho-Prabhu N, Lukas M, Bruining DH, El-Hachem S, Charles RJ, Chen Y, Sood A, Mao R, Loras C, Dulai PS, Picoraro JA, Chiorean M, Lukas M, Shergill A, Silverberg MS, Sandborn WJ, Bernstein CN. Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol 6(6):482-497. 2021
  16. Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 56(6):489-526. 2021
  17. Asonuma K, Kobayashi T, Nakano M, Sagami S, Kiyohara H, Matsubayashi M, Morikubo H, Miyatani Y, Okabayashi S, Yamazaki H, Kuroki Y, Hibi T. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflamm Bowel Dis. Apr 13;izab062.doi:10.1093/ibd/izab062. Online ahead of print. 2021
  18. D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 9(4):451-460. 2021
  19. Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T, on behalf of the HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 6(6):429-437. 2021
  20. Morikubo H, Kobayashi T, OzakiR, Okabayashi S, Kuronuma S, Takeuchi O, Shiba T, Kiyohara H, Matsubayashi M, Sagami S, Nakano M, Ikezaki O, Hisamatsu T, Tanaka Y, Hibi T. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. J Gastroenterol Haepatol 36(8)2116-2124. 2021
  21. Kobayashi T (Corresponding author),Udagawa E, Hibi T. Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. Digestion Online ahead of print. 2021
  22. Kobayashi T, Uda A, Udagawa E, Hibi T. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. J Crohns Colitis. 14(5):617-623. 2020
  23. Kakuta Y, Izumiyama Y, Okamoto D, Nakano T,Ichikawa R, Naito T, Moroi R, Kuroha M, Kanazawa Y, Kimura T, Shiga H, Kudo H, Minegishi N, Kawai Y, Tokunaga K,Nagasaki M,Kinouchi Y, Suzuki Y, Masasmune A; MENDEL study group(Kobayashi T). High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codo n 18 rendering the NUDT15 diplotype. J Gastroenterol. 55(1):67-77. 2020
  24. Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol. 55(2):169-180. 2020
  25. Sandborn WJ, Baert F, Danese S, Krznarić Z, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D’Haens G, Vermeire S. Efficacy and Safety of a New Vedolizumab Subcutaneous Formulation in Ulcerative Colitis: VISIBLE 1 Randomized Trial. Gastroenrterol. 158(3):562-572. 2020
  26. Naganuma M, Kobayashi T, Nasuno M, Motoya S, Kato S, Matsuoka K, Hokari R, Watanabe C, Sakamoto H, Yamamoto H, Sasaki M, Watanabe K, Iijima H, Endo Y, Ichikawa H, Ozeki K, Tanida S, Ueno N, Fujiya M, Sako M, Takeuchi K, Sugimoto S, Abe T, Hibi T, Suzuki Y, Kanai T. Significance of Conducting 2 Types of Fecal Tests in Patients with Ulcerative Colitis. Clin Gastroenterol Hepatol. 18(5):1102-1111. 2020
  27. Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: a claims database analysis. J Gastroenterol Hepatol. 35(2):225-232. 2020
  28. Nanki K, Fujii M, Shimokawa M, Matano M, Nishikori S, Date S, Takano A, Toshimitsu K , Ohta Y, Takahashi S, Sugimoto S, Ishimaru K, Kawasaki K, Nagai Y, Ishii R, Yoshida K1, Sasaki N, Hibi T, Ishihara S, Kanai T, Sato T. Somatic inflammatory gene mutations in human ulcerative colitis epithelium. Nature. 577(7789):254-259. 2020
  29. Saruta M, Park DI, Kim YH, Yang SK, Jang BI, Cheon JH, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick KJ, Cataldi F, Watanabe M, Hibi T. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. Intest Res. 18(1):45-55. 2020
  30. Hibi T, Naganuma M, Oda E, Yamada Y, Chujoh Y, Yoshihara R, Watanabe M. Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Intest Res. 18(1):56-68. 2020
  31. Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T. Ulcerative Colitis:Disease Burden,Impact on Daily Life,anc Reluctance to Consult Medical Professionals:Results from a Japanese Internet Survey. Inflammatory Intestinal Diseases 5(1):27-35. 2020
  32. S Bamba, R Sakemi, T Fujii, T Takkeda, S Fujioka, K Takenaka, H Kitamoto, S Umezawa, H Sakuraba, T Inokuchi, N Fukata, S Mizuno , M Yamashita , S Shinzaki , H Tanaka, H Takedatsu, R Ozaki, K Moriya, M Ishii, T Kinjo ,K Ozeki, M Ooi, R Hayashi, K Kakimoto, Y Shimodate, K Kitamura, A Yamada , A Sonoda, Y Nishida, K Yoshioka, S Ashizuka, F Takahashi, T Shimokawa, T Kobayashi, A Andoh, T Hibi. A Nationwide, Multi-Center, Retrospective Study of Symptomatic Small Bowel Stricture in Patients With Crohn's Disease. J Gastroenterol. 55(6):615-626. 2020
  33. Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of Apheresis as Maintenance Therapy for Patients With Ulcerative Colitis in an Open-Label Prospective Multicenter Randomised Controlled Trial. J Gastroenterol. 55(4):390-400. 2020
  34. Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Effects of Vedolizumab in Japanese Patients With Crohn's Disease: A Prospective, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial With Exploratory Analyses. J Gastroenterol. 55(3):291-306. 2020
  35. Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, and Hibi T. Ulcerative colitis. Nat Rev Dis Primers 6(1):74. 2020
  36. Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Intest Res 2020 Aug 18. doi: 10.5217/ir.2020.00026. Online ahead of print. 2020
  37. Okabayashi S, Kobayashi T, Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intestinal Research. 17(2):218-226. 2019
  38. Hibi T, Motoya S, Ashida T, Sai S, Sameshima Y, Nakamura S, Maemoto A, Nii M, Sullivan BA, Gasser RA, Suzuki Y. Efficacy and safety of abrilumab, α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res. 17(3):375-386. 2019
  39. Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study). J Crohns Colitis. 13(9):1097-1104. 2019
  40. Sagami S, Kobayashi T, Kikkawa N, Umeda S, Nakano M, Takahiko T, Okabayashi S, Hibi T. Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. PLoS One. 14(2):e0212404. 2019
  41. Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One. Feb26;14(2).e0212989. 2019
  42. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group (Kobayashi T). Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 381(13):1201-1214. 2019
  43. Oka A, Mishima Y, Liu B, Herzog JW, Steinbach EC, Kobayashi T, Plevy SE, Sartor RB. Phosphoinositide 3-Kinase P110δ-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. Cells. 21;8(10)1121. 2019
  44. Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis. Aug;4(3):79–96. 2019
  45. Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA, Watanabe N. Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database Syst Rev. Aug 29;8:CD012893. doi: 10.1002/14651858. 2019
  46. Nakagawa T, Kobayashi T, Nishikawa K, Yamada F, Asai S, Sameshima Y, Suzuki Y, Watanabe M, Hibi T. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 17(4):504-515. 2019
  47. Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T; DIAMOND2 Study Group(Kobayashi T). Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). J Gastroenterol. Oct;54(10):860-870. 2019
  48. Yoshida A, Kamata N, Yamada T, Yokoyama Y, Omori T, Fuji T, Hayashi Rm Kinjoh T, Matsui A, Fukata N, Takahashi S, Sakemil R, Ogata N, Ashizuka S, Bamba S, Ooi M, Kanmura S, Endo K, Yoshino T, Tanaka H, Morizane T, Shinzaki S, Kobayashi T. Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease. Inflamm Intest Dis. 3(4):167-172. 2019
  49. Naganuma M, Sugimoto S, Suzuki H, Matsuno Y, Araki T, Shimizu H, Hayashi R, Fukuda T, Nakamoto N, Iijima H, Nakamura S, Kataoka M, Tamura Y, Tatsumi K, Hibi T, Suzuki Y, Kanai T; INDIGO survey Group. Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. J Gastroenterol. 54(10):891-896. 2019
  50. Suzuki Y, Watanabe M, Matsui T, Motoya S, Hisamatsu T, Yuasa H, Tabira J, Isogawa N, Tsuchiwata S, Arai S, Hibi T. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients With Active Ulcerative Colitis. Inflamm Intest Dis. Oct;4(4):131-143. 2019
  51. Hajime Yamazaki, Katsuyoshi Matsuoka,Jovelle Fernandez,Toshifumi Hibi,Mamoru Watanabe,Tadakazu Hisamatsu, Shunichi Fukuhara1. Ulcerative Colitis Outcomes Research in Japan: Protocol for an Observational Prospective Cohort Study of YOURS (YOu and Ulcerative Colitis: Registry and Social Network). BMJ Open Sep 8;9(9):e030134. 2019
  52. Naganuma M, Aoyama N, Tada T, Kobayashi K, Hirai F, Watanabe K, Watanabe M, Hibi T. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol 53(4):494-506. 2018
  53. Kobayashi T, Matsuoka K, Yokoyama Y, Nakamura T, Ino T, Numata T, Shibata H, Aoki H, Matsuno Y, Hibi T. A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. J Gastroenterol 53(3):387-396. 2018
  54. Teratani T, Tomita K, Suzuki T, Furuhashi H, Irie R, Nishikawa M, Yamamoto J, Hibi T, Miura S, Minamino T, Oike Y, Hokari R, Kanai T. Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis. J Clin Invest. 128(4):1581-1596. 2018
  55. Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T; ADJUST study group. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. J Gastroenterol Hepatol. 33(5)1031-1038. 2018
  56. Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment. J Gastroenterol Hepatol. 33(1):20-29. 2018
  57. Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management. J Gastroenterol Hepatol. 33(1):30-36. 2018
  58. Umeno J, Esaki M, Hirano A, Fuyuno Y, Ohmiya N, Yasukawa S, Hirai F, Kochi S, Kurahara K, Yanai S, Uchida K, Hosomi S, Watanabe K, Hosoe N, Ogata H, Hisamatsu T, Nagayama M, Yamamoto H, Abukawa D, Kakuta F, Onodera K, Matsui T, Hibi T, Yao T, Kitazono T, Matsumoto T; CEAS study group. Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn's disease. J Gastroenterol. 53(8):907-915. 2018
  59. Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S, Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T; INDIGO Study Group. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. Gastroenterology. 154(4):935-947. 2018
  60. Ueno A, Jeffery L, Kobayashi T, Hibi T, Ghosh S, Jijon H. Th17 plasticity and its relevance to inflammatory bowel disease. J Autoimmun. 87:38-49. 2018
  61. Komoto S, Matsuoka K, Kobayashi T, Yokoyama Y, Suzuki Y, Hibi T, Miura S, Hokari R. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. J Gastroenterol Hepatol. 33(8):1485-1491. 2018
  62. Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 53(3):305-353. 2018
  63. Matsuoka K, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K, Yoshimura N, Hibi T. Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Dig Dis Sci. 63(7)1910-1919. 2018
  64. Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res. 16(1):4-16. 2018
  65. Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res. 16(1):17-25. 2018
  66. Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, for the DIAMOND study group. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology. 16(4):542-549. 2018
  67. Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T. Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intest Res. 16(2)168-177. 2018
  68. Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 16（2）233-245. 2018
  69. Ogata H, Yokoyama T, Mizushima S, Hagino A, Hibi T. Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. Intest　Res. 16（2）:255-266. 2018
  70. Okabayashi S, Kobayashi T, Nakano M, Toyonaga T, Ozaki R, Carla Tablante M, Kuronuma S, Takeuchi O, Hibi T. A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis. Inflamm Bowel Dis. 24(11):2404-2412. 2018
  71. Komoto S, Higashiyama M, Watanabe C, Suzuki Y, Watanabe M, Hibi T, Takebayashi T, Asakura K, Nishiwaki Y, Miura S, Hokari R. Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis: A nationwide survey data in Japan. J Gastroenterol Hepatol. 33(11):1839-1843. 2018
  72. Hosoe N, Nakano M, Takeuchi K, Endo Y, Matsuoka K, Abe T, Omori T, Hayashida M, Kobayashi T, Yoshida A, Mizuno S, Yoshihiro N, Naganuma M, Kanai T, Watanabe M, Ueno F, Suzuki Y, Hibi T, Ogata H. Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis-Capsule Scoring of Ulcerative Colitis. Inflamm Bowel Dis. 24(12):2641-2647. 2018
  73. Ozaki R, Kobayashi T, Okabayashi S, Nakano M, Morinaga S, Hara A, Ohbu M, Matsuoka K, Toyonaga T, Saito E, Hisamatsu T, Hibi T. Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Normal Mucosa. J Crohns Colitis. 12(11):1288-1294. 2018
  74. Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group. Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Intest Res. 16(3):494-498. 2018
  75. Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS One. 13(8):e0201956. 2018
  76. Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T. Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. Inflamm Intest Dis. 2(4):228-235. 2018
  77. Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, Tanaka H, Ozeki K, Takahashi S, Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res. 16(4):609-618. 2018
  78. Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu T, Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T. 5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. Intest Res. 16(4):635-640. 2018
  79. Sagami S, Kobayashi T, Hibi T. Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. Inflamm Intest Dis. 3(1):1-10. 2018
  80. Okabayashi S, Kobayashi T, Hibi T. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Inflamm Intest Dis. 3(1):25-31. 2018
  81. Imaeda H, Hibi T. The Burden of Diverticular Disease and Its Complications: West versus East. Inflamm Intest Dis. 3(2):61-68. 2018
  82. Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 53(3):305-353. 2018
  83. Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group. Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Intestinal Research 16(3):494-498. 2018
  84. Kobayashi T, Hishida A, Tanaka H, Nuki Y, Bamba S, Yamada A, Fujii T, Shinzaki S, Yokoyama Y, Yoshida A, Ozeki K, Ashizuka S, Kamata N, Nanjo S, Kakimoto K, Nakamura M, Matsui A, Yamauchi R, Takahashi S, Tomizawa T, Yoshino T, Hibi T. Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study. Inflamm Bowel Dis 23(12):2245-2251. 2017
  85. Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res. 15(4):475-486. 2017
  86. Hirai F, Andoh A, Ueno F, Watanabe K, Ohmiya N, Nakase H, Kato S, Esaki M, Endo Y, Yamamoto H, Matsui T, Iida M, Hibi T, Watanabe M, Suzuki Y, Matsumoto T. Efficacy of endoscopic balloon dilation for small bowel strictures in patients with Crohn's disease: A nationwide, multi-center, open-label, prospective cohort study. J Crohns Colitis. 12(4):394-401. 2017
  87. Yokoyama T, Ohta A, Motoya S, Takazoe M, Yajima T, Date M, Nii Masahiro, Nagy P, Suzuki Y, Hibi T. Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study. Inflammatory Intestinal Diseases 2(3)154-162. 2017
  88. Hibi T, Panaccione R, Katafuchi M, Yokoyama K, Watanabe K, Matsui T, Matsumoto T, Travis S, Suzuki Y. The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management.J Crohns Colitis. 11(11): 1302-1308 2017
  89. Toyonaga T, Kobayashi T, Nakano M, Saito E, Umeda S, Okabayashi S, Ozaki R, Hibi T. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS One 21;12(9) :e0185131 2017
  90. Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group.Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.Aliment Pharmacol Ther. 46(9):873-882 2017
  91. Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson AM, Thakkar RB, and Hibi T: Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial. Intest Res. 15(3):395-401 2017
  92. Ogata H, Aoyama N, Mizushima S, Hagino A, and Hibi T: Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study.Intest Res 15(3):368-379 2017
  93. Ogata H, Ohori A, Nishino H, Mizushima S, Hagino A, and Hibi T: Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study.Intest Res 15(3):358-367 2017
  94. Teratani T, Tomita K, Suzuki T, Furuhashi H, Irie R, Hida S, Okada Y, Kurihara C, Ebinuma H, Nakamoto N, Saito H, Hibi T, Miura S, Hokari R, and Kanai T: Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling. J Hepatol. 67(4):780-790 2017
  95. Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M: Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 52(9):1079. 2017
  96. Nagahori M, Kochi S, Hanai H, Yamamoto T, Nakamura S, Omuro S, Watanabe M, Hibi T; OPTIMUM Study Group : Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.BMC Gastroenterol. 17(1):47 2017
  97. Suzuki Y, Iida M, Ito H, Nishino H, Ohmori T, Arai T, Yokoyama T, Okubo T, Hibi T : 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial : Inflamm Bowel Dis 23(5):822-832 2017
  98. Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y : Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).J Gastroenterol. 52(10):1101-1111 2017
  99. Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M : Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.J Gastroenterol 52:1031–1040 2017
  100. Umeda S, Serizawa H, Kobayashi T, Toyonaga T, Saito E, Nakano M, Higuchi H, Tsunematsu S, Watanabe N, Hibi T, Morinaga S: Clinical significance of human intestinal spirochetosis: a retrospective study.Nihon Shokakibyo Gakkai Zasshi 114(2):230-237 2017
  101. Okabayashi S, Kobayashi T [corresponding author], Sujino T, Ozaki R, Umeda S, Toyonaga T, Saito E, Nakano M, Tablante MC, Morinaga S, and Hibi T: Steroid-refractory extensive enteritis complicated with ulcerative colitis successfully treated with adalimumab. Intest Res 15(4):535-539 2017
  102. Shimizu S, Kobayashi T, Tomioka H, Ohtsu K, Matsui T, Hibi T: Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey.J Gastroenterol 52(3):308-314 2017
  103. Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T:Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.J Crohns Colitis 11(1) : 84-91 2017
  104. Ueno F, Nakayama Y, Hagiwara E, Kurimoto S, and Hibi T: Impact of Inflammatory bowel disease on Japanese patients' quality of life:results of a patient questionnaire survey. J Gastroenterol 52(5):555-567 2017
  105. Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, Ishida T, Kato S,Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, and Hibi T; Diamond Study Group :Adalimumab monotherapy and a combination with azathioprine for Crohn's disease:A prospective,randomized trial.J Crohns Colitis 10(11):1259-1266 2016
  106. Toyonaga T, Matsuura M, Mori K, Honzawa Y, Minami N, Yamada S, Kobayashi T, Hibi T, and Nakase H : Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages.Sci Rep.13；6：35014 2016
  107. Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suziki Y, Watanabe M, and Hibi T: Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-associated Colorectal Cancer.Gastroenterology 151(6):1122-1130 2016
  108. Ogata H, Watanabe M, Matsui T, Hase H, Okayasu M, Tsuchiya T, Shinmura Y, and Hibi T: Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease.J Crohns Colitis 10(9):1033-41 2016
  109. Naganuma M, Aoyama N, Suzuki Y, Nishino H, Kobayashi K, Hirai F, Watanabe K, and Hibi T: Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. 2016
  110. Kobayashi T, Umeno J, Hisamatsu T, Esaki M, Matsui T, Matsumoto T, and Hibi T: Chronic nonspecific multiple ulcers of the small intestine (CNSU) and chronic enteropathy associated with SLCO2A1 (CEAS). Nihon Shokakibyo Gakkai Zasshi 113(8):1380-5 2016
  111. Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Osaki K, Watanabe M, and Hibi T: First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post-hoc analysis. J Gastroenterol 51(3):241-51 2016
  112. Sawada K, Ohdo M, Ino T, Nakamura T, Numata T, Shibata H, Sakou J, Kusada M, and Hibi T: Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. Ther Apher Dial 20(2):197-204 2016
  113. Imaeda H, Nakajima K, Hosoe N, Nakahara M, Zushi S, Kato M, Kashiwagi K, Matsumoto Y, Kimura K, Nakamura R, Wada N, Tsujii M, Yahagi N, Hibi T, Kanai T, Takehara T, and Ogata H: Percutaneous endoscopic gastrostomy under steady pressure automatically controlled endoscopy:First clinical series. World J Gastrointest Endosc 10;8(3):186-91 2016
  114. Suzuki Y, Iida M, Ito H, Tachikawa N, and Hibi T: Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease. Drugs R D 16(1):35-43 2016
  115. Suzuki Y, Iida M, Ito H, Saida I, and Hibi T: Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. Intest Res 14(1):50-9 2016
  116. Togawa K, Matsuzaki J, Kobayakawa M, Fukushima Y, Suzaki F, Kasugai K, Nishizawa T, Naito Y, Hayakawa T, Kamiya T, Andoh T, Yoshida H, Tokura Y, Nagata H, Mori M, Kato K, Hosoda H, Takebayashi T, Miura S, Uemura N, Joh T, Hibi T, and Suzuki H: Association of baseline plasma des-acyl ghrelin level with the response to rikkunshito in patients with functional dyspepsia. J Gastroenterol Hepatol 31(2):334-41, 2016
  117. Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease: Asia Pacific Consensus Statements on Crohn’n disease Part2: Management. J Gastroenterol Hepatol 31(1):56-68 2016
  118. Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease: Asia Pacific Consensus Statements on Crohn’n disease. Part1: Definition,diagnosis and epidemiology.(Asia Pacific Crohn’n Disease Consensus—Part 1). J Gastroenterol Hepatol 31(1):45-55 2016
  119. Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y: Infliximab therapy for intestinal,neurological,and vascular involvement in Behcet disease:Efficacy,safety,and pharmacokinetics in a multicenter,prospective,open-label,single-arm phase 3 study.Medicine(Baltimore) 95:(24)e3863 2016
  120. Hosoe N, Matsukawa S, Kanno Y, Naganuma M, Imaeda H, Ida Y, Tsuchiya Y, Hibi T, Ogata H,and Kanai T: Cross-sectional small intestinal surveillance of maintenance hemodialysis patients using video capcule endoscopy:SCHEMA study.Endosc Int Open4(5):E589-96 2016
  121. Komoto S, Motoya S, Nishiwaki Y, Matsui T, Kunisaki R, Matsuoka K, Yoshimura N, Kagaya T, Naganuma M, Hida N, Watanabe M, Hibi T, Suzuki Y, Miura S, Hokari R ; Japanese study group for pregnant woman with IBD: Pregnancy outcome in woman with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy:a multicenter study from Japan.Intest ResApr;14(2):139-45 2016
  122. Watanabe C, Komoto S, Tomita K, Hokari R, Tanaka M, Hirata I, Hibi T, Kaunitz JD, Miura S: Endoscopic and clinical evalution of treatment and prognosis of Cronkhite-Canada Syndrome:a Japanese nationwide survey.J Gastroenterol Apr;51(4):327-36 2016
  123. Wada Y, Hisamatsu T, Naganuma M, Matsuoka K, Okamoto S, Inoue N, Yajima T, Kouyama K, Iwao Y, Ogata H, Hibi T, Abe T,and Kanai T:Risk factors for decreased bone mineral density in inflammatory bowel disease:A cross-sectional study.Clin Nutr Dec;34(6):1202-9 2015
  124. Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, Watanabe K, Hibi T;AJM300 Study Group:Safety and Efficacy of AJM300,an Oral Antagonist of α4 Integrin,in Induction Therapy for Patients with Active Ulcerative Colitis.Gastroenterology Dec;149(7):1775-1783 2015
  125. Umeno J, Hisamatsu T, Esaki M, Hirano A, Kubokura N, Asano K, Kochi S, Yanai S, Fuyuno Y, Shimamura K, Hosoe N, Ogata H, Watanabe T, Aoyagi K, Ooi H, Watanabe K, Yasukawa S, Hirai F, Matsui T, Iida M, Yao T, Hibi T, Kosaki K, Kanai T, Kitazono T, Matsumoto T.A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene,Encoding a Prostaglandin Transporter.PLoS Genet Nov 5;11(11) 2015
  126. Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, Nakagawa T, Fukuchi T, Motoya S, Kunisaki R, Kato S, Hirai F, Ishiguro Y, Tanida S, Hiraoka S, Mitsuyama K, Ishihara S, Tanaka S, Otaka M, Osada T, Kagaya T, Suzuki Y, Nakase H, Hanai H, Watanabe K, Kashiwagi N, Hibi T.An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease.BMC Gastroenterol Nov 19;15:163 2015
  127. Hisamatsu T, Ono N, Imaizumi A, Mori M, Suzuki H, Uo M, Hashimoto M, Naganuma M, Matsuoka K, Mizuno S, Kitazume MT, Yajima T, Ogata H, Iwao Y, Hibi T, Kanai T..Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission.PLoS One Oct 16;10(10) 2015
  128. Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T. Circulating Interleukin 6 and Albumin,and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn’s Disease:A Prospective Clinical Trial Inflamm Bowel Dis. Sep;21(9):2114-22 2015
  129. Kawa S, Okazaki K, Notohara K, Watanabe M, Shimosegawa T ; Study Group for Pancreatitis Complicated with Inflammatory Bowel Disease organized by The Research Committee for Intractable Pancreatic Disease(Chairman:Tooru Shimosegawa)and The Research Committee for Intractable Inflammatory Bowel Disease(Chairman:Mamoru Watanabe),both of which are supported by the Ministry of Health,Labour,and welfare of Japan.Autoimmune pancreatitis Complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis. 2015
  130. Takayama T, Okamoto S, Hisamatsu T, Naganuma M, Matsuoka K, Mizuno S,Bessho R, Hibi T, Kanai T. Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Cclitis after Cytoapheresis Therapy.PLoS One Jun 25;10(6):e0131197 2015
  131. Chu PS, Ebinuma H, Nakamoto N, sugiyama K, Usui S, Wakayama Y, Taniki N, Yamaguchi A, Shiba S,Yamagishi Y, Wakita T, Hibi T, Saito H, Kanai T, Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-lnterferon/Ribavirin Therapy in Chronic Hepatitis C.PLoS One May;10(5):e0125664. 2015
  132. Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T,Ishigatsubo Y, Suzuki Y, Nagahori M, Motoya S, Nakamura S, Arora V, Robinson AM, Thakkar Rb, Hibi T.Adalimumab for the Treatment of Japanese Patients With Intestinal Behcet`s Disease.Clin Gastroenterol Hepatol May;13(5):940-8 2015
  133. Sato H, Tomita K, Yasue C, Umeda R, Ebinuma H, Ogata S, Du W, Soga S, Maruta K, Yasutake Y, Narimatsu K, Usui S, Watanabe C, Komoto S, Teratani T, Suzuki T, Yokoyama H, Saito H, Nagao S, Hibi T, Miura S, Kanai T, and Hokari R:Pregnant woman with non-comatose autoimmune acute liver failure in the second trimester rescued using medical therapy:A case report.Hepatol Res Mar;45(3):349-55 2015
  134. Sakuraba A, Okamoto S, Matsuoka K, Sato T, Naganuma M, Hisamatsu T, Iwao Y, Ogata H, Kanai T, and Hibi T:Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn’s disease.Digestion 91(3):233-8 2015
  135. Oryoji D, Hisamatsu T, Tsuchiya K, Umeno J, Ueda S, Yamamoto K, Matsumoto T, Watanabe M, Hibi T, and Sasazuki T. Associations of HLA class I alleles in Japanese patients with Crohn's disease.Genes Immun Jan-Feb;16(1):54-6 2015
  136. Yokoyama Y*, Matsuoka K*, Kobayashi T*[*First authorship shared], Sawada K, Fujiyoshi T, Ando T, Ohnishi Y, Ishida T, Oka M, Yamada M, Nakamura T, Ino T, Numata T, Aoki H, Sakou J, Kusada M, Maekawa T, Hibi T. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. J Crohn Colitis Sep 8(9):981-991 2014
  137. Steinbach EC, Kobayashi T, Russo SM, Sheikh SZ, Gipson G, Kennedy S, Uno JK, Mishima Y, Borst LB, Liu B, Herfarth H, Ting J, Sartor RB, Plevy SE. Innate PI3K p110δ regu lates Th1/Th17 development and microbiota-dependent colitis. J Immunol Apr 192(8):3958-68 2014
  138. Suzuki Y, Motoya S, Hanai H, Hibi T, Anne M.Robinson, Nael M. Mostafa, Jingdong Chao, Vipin Arora, Anne Camez, Roopal B, Thakkar, Watanabe M. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 49:283-294 Feb 2014
  139. Takabayashi K, Kashiwagi K, Kawata T, Hibi T, Ogata H, Yahagi N, Kitagawa Y, Shigematsu N, Kanai T. Continuous low-dose irradiation by l-125 seeds induces apoptosis of gastric cancer cells regardless of histological origin. Cancer Biol Ther 15(1):81-8 Jan 2014.
  140. Esaki M, Matsumoto T, Watanabe K, Hibi T, Matsumoto T, Nouda S, Higuchi K, Ohmiya N, Goto H, Kurokawa S, Motoya S, Watanabe M. Use of capsule endoscopy in patients with Crohn's disease in Japan: a multicenter survey. J Gastroenterol Hepatol 29(1):96-101 Jan 2014.
  141. Mikami Y, Mizuno S, Nakamoto N, Hibi T, Yoshimura A, Kanai T. :Macrophages and Dendritic Cells Emerge in the Liver during Intestinal Inflammation and Predispose the Liver to Inflammation. PLoS One 9(1):e84619 Jan 2014
  142. Nakamura S, Yaguchi T, Kawamura N, Hibi T, Kawakami Y. :TGF-β1 in Tumor Microenvironments Induces Immunosuppression in the Tumors and Sentinel Lymph Nodes and Promotes Tumor Progression. J Immunother Feb 37(2):63-72 2014
  143. Hibi T, Sakuraba A, Watanabe M, : C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J Gastroenterol,49(2):254-62 Feb 2014
  144. Sandborn WJ, Feagan BG, Marano C, Rutgeerts P, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Hibi T; PURSUIT-SC Study Group: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate to Severe Ulcerative Colitis. Gastroenterology 146(1):85-95 , 2014
  145. Tomita K, Teratani T, Suzuki T, Hibi T. Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59(1):154-69 , 2014
  146. Hisamatsu T, Ueno F, Matsumoto T, Hibi T. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol 49(1):156-62 Jan 2014
  147. Akagi H, Higuchi H, Sumimoto H, Hibi T. Suppression of myeloid cell leukemia-1(Mcl-1)enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 16(1):100-10 2013
  148. Takayama T, Kanai T, Matsuoka K, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis 7(2):e49-54 2013
  149. Sujino T, Ebinuma H, Hosoe N, Hibi T. Epstein-barr virus-associated gastritis: a case report. Dig Dis Sci 58(3):883-6 2013
  150. Uo M, Hisamatsu T, Miyoshi J, Hibi T. Mucosal CXCR4+lgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcyR-mediated CD14 macrophage activation.Gut 62(12):1734-44 2013
  151. Kawakami A, Tanaka M, Nishigaki M, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K. :Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 48(9):1006-15 2013
  152. Mizuno S, Yamagishi Y, Ebinuma H, Hibi T. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol 6(2):188-192 2013
  153. Matsuzaki J, Suzuki H, Tsugawa H, Hibi T. Bile acids increase levels of microRNAs221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology 145(6):1300-11 2013
  154. Hirata T, Tomita K, Kawai T, Hibi T. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study(FANTASY). Int J Endocrinol 2013:587140 2013
  155. Nishizawa T, Suzuki H, Takahashi M, Hibi T. Effect of ursodeoxycholic acid and endoscopic sphincterotomy in long-term stenting for common bile duct stones. J Gastroenterol Hepatol 28(1);63-7 2013
  156. Hirata K, Suzuki H, Matsuzaki J, Hibi T. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy. J Clin Biochem Nutr 52(2);172-8 2013
  157. Mogami S, Suzuki H, Tsugawa H, Hibi T. Impaired heme oxygenase-1 induction in the gastric antrum induces disruption of the interstitial cells of Cajal network in a rat model of streptozotocin-induced diabetes. Neurogastroenterol Motil 25(7);609-e465 2013
  158. Kishikawa H, Nishida J, Takarabe S, Hibi T. "Circular reddish lesions": a possibly characteristic endoscopic finding in Henoch-Schonlein purpura. Endoscopy Suppl 2 E33-4 2013
  159. Mizuno S, Yamagishi Y, Ebinuma H, Hibi T. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clim J Gastroenterol 6(2);188-192 2013
  160. Koike S, Sujino T, Ohmori H, Hibi T, Ono T. Gastric emptying rate in subjects with malocclusion examined by [13C] breath test. J Oral Rehabil 40(8);574-581 2013
  161. Nishizawa T, Suzuki H, Takahashi M, Hibi T. Delay of second-line eradication therapy for H. pylori can increase eradication failure. J Gastroenterol Hepatol 28(10):1608-10 2013
  162. Liu DY, Pan CS, Liu YY, Hibi T, Liu HN, Han JY Huang Qi Jian Zhong Pellet Attenuates TNBS-Induced Colitis in Rats via Mechanisms Involving Improvement of Energy Metabolism. Evid Based Complement Alternat Med vol.2013:1-14 2013
  163. Watanabe M, Nishino H, Sameshima Y, Hibi T. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study Alimentary Pharmacology Ther 38(3);264-73 2013
  164. Suzuki Y, Motoya S, Takazoe M, Hibi T. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: A multicentre, double-blind, randomized, parallel-group Phase Ⅱstudy J Crohns Colitis 7(3):239-247 2013
  165. Hirano Y, Takeuchi H, Oyama T, Hibi T, Kitagawa T. Minimally invasive surgery for esophageal epiphrenic diverticulum: the results of 133 patients in 25 published series and our experience Surg Today 43(1):1-7 2013
  166. Matsumoto A, Kanai T, Mikami Y, Hibi T. IL-22-producing RORγt-dependent innate lymphoid cells play a novel protective role in murine acute hepatitis. PLoS One 8(4):e62853 2013
  167. Miyoshi J, Matsuoka K, Inoue N, Hibi T. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis 7(12):e609-14 2013
  168. Miyake M, Toguchi H, Nishibayashi T, Hibi T. Establishment of novel prediction system of intestinal absorption in humans using human intestinal tissues. J Pharm Sci 102(8):2564-71 2013
  169. Hayashi A, Sato T, Kamada N, Hibi T, Roers A, Yagita H, Ohteki T, Yoshimura A, Kanai T.: A Single Strain of Clostridium butyricum Induces Intestinal IL-10-Producing Macrophages to Suppress Acute Experimental Colitis in Mice. Cell Host Microbe 13(6):711-22 2013
  170. Hirata K, Suzuki H, Imaeda H, Hibi T. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer 109(2):379-86 , 2013
  171. Funakoshi S, Hashiguchi A, Teramoto K, Hibi T. Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature. Oncol Lett 5(1):117-122 2013
  172. Takahashi T, Suzuki H, Imai T, Hibi T. Musashi-1 post-transcriptionally enhances phosphotyrosine-binding domain-containing m-Numb protein expression in regenerating gastric mucosa. PLoS One 8(1):e53540 2013
  173. Handa T, Kanai T, Sato T, Hibi T: Dendritic cells administered intrarectally penetrate the intestinal barrier to break intestinal tolerance via Th2-medeiated colitis in mice. Immunol Lett 150(1-2):123-9 2013
  174. Nakamura Y, Kanai T, Saeki K,and Hibi T: CCR2 knockout exacerbates cerulein-induced chronic pancreatitis with hyperglycemia via decreased GLP-1 receptor expression and insulin secretion. Am J Physiol Gastrointest Liver Physiol 304(8):G700-7, 2013
  175. Chu PS, Nakamoto N, Ebinuma H,and Hibi T: C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice. Hepatology 58(1):337-50, 2013
  176. Hosoe N, Matsuoka K, Naganuma M,and Hibi T: Applicability of second-generation colon capsule endoscope to ulcerative colitis: A clinical feasibility study. J Gastroenterol Hepatol 28(7):1174-9, 2013
  177. Sato A, Saito Y, Sugiyama K, Hibi T,and Saito H: Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells. J Cell Biochem 114(9):1987-96, 2013
  178. Yoneno K, Hisamatsu T, Shimamura K,and Hibi T: TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 139(1):19-29, 2013
  179. Ueno F, Matsui T, Matsumoto T,and Hibi T: Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology.: Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol 48(1):31-72, 2013
  180. Hisamatsu T, Kanai T, Mikami Y,and Hibi T: Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther 137(3):283-97, 2013
  181. Chang J, Hisamatsu T, Shimamura K,and Hibi T: Activated hepatic stellate cells mediate the differentiation of macrophages. Hepatol Res 43(6):658-69, 2013
  182. Kabashima-Niibe A, Higuchi H, Takaishi H,and Hibi T: Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Cancer Sci 104(2):157-64, 2013
  183. Suzuki Y, Motoya S, Takazoe M,and Hibi T: Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis 7(3):239-47, 2013
  184. Nakashita M, Suzuki H, Miura S,and Hibi T: Attenuation of acetic acid-induced gastric ulcer formation in rats by glucosylceramide synthase inhibitors. Dig Dis Sci 58(2):354-62, 2013
  185. Saito Y, Suzuki H, Imaeda H,and Hibi T: The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells . Int J Cancer 132(8):1751-60, 2013
  186. Kobayashi T, Russo SM, Steinbach EC, Russo SM, Matsuoka K, Nochi T, Maharshak N, Borst LB, Hostager B, Garcia-Martinez JV, Rothman PB, Kashiwada M, Sheikh SZ, Murray PJ,and Plevy SE: NFIL3 deficient mice develop microbiota dependent, IL-12/23 driven spontaneous colitis. J Immunol 15;192(4):1918-27, 2014
  187. Matsuzaki J, Suzuki H, Okuda S,and Hibi T: Biliary findings assist in predicting enlargement of intraductal papillary mucinous neoplasms of the pancreas. Clin Gastroenterol Hepatol 11(5):548-54, 2013
  188. Onyiah JC, Sheikh SZ, Maharshak N, Kobayashi T, Mackey LC, Hansen JJ, Moeser AJ, Rawls JF, Borst LB, Otterbein LE,and Plevy SE: Carbon monoxide and heme oxygenase-1 prevent intestinal inflammation in mice by promoting bacterial clearance. Gastroenterology 144(4):789-98, 2013
戻る
サイトマップサイトマップページトップページトップ